The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life following tumor-infiltrating lymphocyte (TIL) therapy with commercial lifileucel in metastatic melanoma: Real-world longitudinal patient-reported outcomes.
 
Kimberly Ward
Research Funding - Iovance Biotherapeutics (Inst)
 
Denise Kalos
No Relationships to Disclose
 
Jamie Chau
Employment - Moffitt Cancer Center
Research Funding - Iovance Biotherapeutics (Inst); Valar Labs (Inst)
 
Christopher Otteni
Employment - DocPanel; Envision Physician Services (I); Moffitt Cancer Center
Research Funding - Iovance Biotherapeutics (Inst)
 
Lianicet Rodriguez-Alfonso
No Relationships to Disclose
 
Ella Vieira
No Relationships to Disclose
 
Karla Adams
No Relationships to Disclose
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Veru
Consulting or Advisory Role - MyCareGorithm
Research Funding - Turnstone Bio
Travel, Accommodations, Expenses - A2Bio
 
John Mullinax
Consulting or Advisory Role - Iovance Biotherapeutics; Lyell Immunopharma; Merit Medical Systems
Research Funding - Intellia Therapeutics; Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - IP licensed to Iovance by my institution on which I am an inventor.
 
Frederick Locke
Employment - Moffitt Cancer Center
Consulting or Advisory Role - A2 Biotherapeutics; Adaptimmune; Adaptive Biotechnologies; Alimera Sciences; Amgen; AstraZeneca; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Pfizer; Poseida; Sana Biotechnology; Takeda
Research Funding - 2seventy bio (Inst); Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Jonathan Zager
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Honoraria - Castle Biosciences; Delcath Systems; Merck; Merit Medical Systems; Skyline Diagnostics
Consulting or Advisory Role - Castle Biosciences; Delcath Systems; Philogen; Skyline Diagnostics
Speakers' Bureau - Merit Medical Systems; Skyline Diagnostics
Research Funding - Delcath Systems (Inst); Philogen (Inst)
Patents, Royalties, Other Intellectual Property - US Patent # 11,779,698; US Patent 10,583,246
Expert Testimony - Gideon Assen; Hinshaw Culbertson; McGowan, Hood, Felder & Phillips, LLC
Travel, Accommodations, Expenses - Merck
 
Matthew Perez
Honoraria - Guidepoint Global; Replimune
Consulting or Advisory Role - Guidepoint Global; Replimune
 
Amod Sarnaik
Stock and Other Ownership Interests - Specicare
Honoraria - Blueprint Oncology; Gerson Lehrman Group; Guidepoint Inc; Iovance Biotherapeutics (Inst); Replimune; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Iovance Biotherapeutics
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Bluprint Oncology Concepts
 
Vernon Sondak
Consulting or Advisory Role - Bristol-Myers Squibb; Merck/Schering Plough; Mural Oncology; Regeneron
Research Funding - Neogene Therapeutics (Inst); Skyline Diagnostics (Inst)
 
Zeynep Eroglu
Consulting or Advisory Role - Natera; Pfizer; Regeneron; Replimune; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
 
Joseph Markowitz
Stock and Other Ownership Interests - Amdocs; Consolidated Edison
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Andrew Brohl
Consulting or Advisory Role - Deciphera
Research Funding - Merck (Inst)
 
Ahmad Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Moderna Therapeutics; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); Nested Therapeutics (Inst); OncoResponse (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst); Werewolf Therapeutics (Inst)
 
Nikhil Khushalani
Stock and Other Ownership Interests - Bellicum Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Delcath Systems; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Merck; Mural Oncology; Nektar; Novartis; Regeneron; Replimune; Sun Pharma
Research Funding - BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); HUYA Bioscience International (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; Sun Pharma
(OPTIONAL) Uncompensated Relationships - T-Knife
 
Lilit Karapetyan
Research Funding - Iovance Biotherapeutics (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - immatics